Genocea Biosciences Stock Forecast, Price & News

Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

Is Genocea Biosciences a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Genocea Biosciences stock.
View analyst ratings for Genocea Biosciences or view top-rated stocks.

How has Genocea Biosciences' stock been impacted by Coronavirus (COVID-19)?

Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNCA stock has decreased by 47.0% and is now trading at $0.97.
View which stocks have been most impacted by COVID-19.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Genocea Biosciences.

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) issued its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter. During the same period last year, the company posted ($0.26) earnings per share.
View Genocea Biosciences' earnings history.

What price target have analysts set for GNCA?

3 equities research analysts have issued twelve-month target prices for Genocea Biosciences' stock. Their forecasts range from $6.00 to $8.00. On average, they expect Genocea Biosciences' share price to reach $6.67 in the next twelve months. This suggests a possible upside of 587.3% from the stock's current price.
View analysts' price targets for Genocea Biosciences or view top-rated stocks among Wall Street analysts.

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the following people:

• Chip Clark, President, Chief Executive Officer & Director
• Diantha Duvall, Chief Financial Officer
• Jessica Baker Flechtner, Chief Scientific Officer
• Thomas Andrew Davis, Chief Medical Officer
• Jacquelyn Sumer, Chief Legal & Compliance Officer

What is William Clark's approval rating as Genocea Biosciences' CEO?

5 employees have rated Genocea Biosciences CEO William Clark on Glassdoor.com. William Clark has an approval rating of 82% among Genocea Biosciences' employees.

Who are some of Genocea Biosciences' key competitors?

Some companies that are related to Genocea Biosciences include SQZ Biotechnologies (SQZ), Acumen Pharmaceuticals (ABOS), Genfit (GNFT), Ambrx Biopharma (AMAM), Surface Oncology (SURF), Gamida Cell (GMDA), Candel Therapeutics (CADL), Harpoon Therapeutics (HARP), Genenta Science (GNTA), Genenta Science (GNTA), aTyr Pharma (LIFE), Jasper Therapeutics (JSPR), Codiak BioSciences (CDAK), DBV Technologies (DBVT) and INmune Bio (INMB).
View all of GNCA's competitors.

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $0.97.

How much money does Genocea Biosciences make?

Genocea Biosciences has a market capitalization of $55.72 million and generates $1.36 million in revenue each year. The biotechnology company earns $-43.71 million in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Genocea Biosciences have?

Genocea Biosciences employs 72 workers across the globe.

What is Genocea Biosciences' official website?

The official website for Genocea Biosciences is www.genocea.com.

Where are Genocea Biosciences' headquarters?

Genocea Biosciences is headquartered at 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at (617) 876-8191, via email at [email protected], or via fax at 617-876-8192.